Exelixis
EXEL
#1697
Rank
S$13.38 B
Marketcap
$46.86
Share price
0.52%
Change (1 day)
65.07%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): $0.38

According to Exelixis's latest financial reports the company's current EPS (TTM) is $0.38. In 2022 the company made an earnings per share (EPS) of $0.77 a decrease over its 2021 EPS that were of $1.00.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$0.38-50.15%
2022$0.77-22.97%
2021$1.00100%
2020$0.50-65.09%
2019$1.43-53.91%
2018$3.09333.96%
2017$0.71-260.61%
2016-$0.44-58.75%
2015-$1.08-42.45%
2014-$1.875.3%
2013-$1.7843.48%
2012-$1.24-264.29%
2011$0.75-165.88%
2010-$1.14-32.54%
2009-$1.70-17.65%
2008-$2.0675.86%
2007-$1.17-25.64%
2006-$1.578.33%
2005-$1.45-42.86%
2004-$2.5430.34%
2003-$1.95-5.23%
2002-$2.06-0.65%
2001-$2.07-51.88%
2000-$4.31

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$4.71 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
$4.28 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
$2.45 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.34 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
$19.04 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
$18.95 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
$2.50 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-$13.45-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-$1.13-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA